New drug combo shows promise against tough skin cancer
NCT ID NCT06624475
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a combination of two immunotherapy drugs (Opdualag) works better than one drug (nivolumab) alone when given before surgery for high-risk basal cell carcinoma. About 30 people with large or hard-to-treat skin cancers will receive either the combo or single drug. The goal is to see if the tumors shrink or disappear before surgery, which could lead to better outcomes and less disfigurement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab and relatlimab (Opdualag)
What this could lead to
If it works, this could offer a more effective pre-surgery treatment for high-risk basal cell carcinoma, potentially reducing tumor size and the need for extensive surgery.
What could go wrong
This is a small, early-phase trial with only 30 participants. The combination may not work better than nivolumab alone, and immune-related side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, Irvine
RECRUITINGIrvine, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94158, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••